Enfortumab vedotin - Wikipedia
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4][7] It is a nectin-4 -directed antibody and microtubule inhibitor conjugate. [4][7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]
Enfortumab vedotin Uses, Side Effects & Warnings - Drugs.com
What is enfortumab vedotin? Enfortumab vedotin is used to treat cancer of the bladder or urinary tract that has spread to other parts of the body (metastatic), or cannot be removed with surgery.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced …
2024年3月6日 · We conducted a phase 3, global, open-label, randomized trial to compare the efficacy and safety of enfortumab vedotin and pembrolizumab with the efficacy and safety of platinum-based...
(enfortumab vedotin-ejfv) for injection, for intravenous use Initial U.S. Approval: 2019 ----- INDICATIONS AND USAGE ----- PADCEV is a Nectin-4-directed antibody and microtubule inhibitor...
PADCEV® (enfortumab vedotin-ejfv) for Advanced Bladder Cancer
WHAT IS PADCEV® (enfortumab vedotin-ejfv)? PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery.
Enfortumab Vedotin Approved for Recurrent Bladder Cancer
2020年1月14日 · Enfortumab vedotin-ejfv (Padcev) has been approved for people with advanced bladder cancer. FDA granted the drug accelerated approval for cancers that have progressed despite previous treatments.
PADCEV® (enfortumab vedotin-ejfv) Official HCP Site
enfortumab vedotin-ejfv (padcev®) + pembrolizumab: the only nccn category 1 preferred 1l treatment option across cisplatin-eligible and cisplatin-ineligible patients with la/muc 1,2
Enfortumab Vedotin-ejfv - NCI - National Cancer Institute
Enfortumab vedotin-ejfv is approved to treat: Urothelial cancer (a type of cancer in the bladder or urinary tract) that has spread. It is used: Alone in adults whose cancer cannot be removed by surgery and who have received platinum chemotherapy and immunotherapy.
Enfortumab vedotin - DrugBank Online
2016年10月21日 · Enfortumab vedotin is an antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
DailyMed - PADCEV EJFV- enfortumab vedotin injection, powder ...
2024年8月1日 · Enfortumab vedotin-ejfv is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline (vc) linker (SGD-1006).